Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemia

Jaime Pérez, José Carlos y Guerra Leal, Liliana Nataly y Cantú Rodríguez, Olga Graciela y Gómez Almaguer, David (2016) Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemia. Revista Brasileira de Hematologia e Hemoterapia, 39 (1). pp. 57-59. ISSN 15168484

Vista previa

Texto 515.pdf - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (315kB) | Vista previa

Resumen

Aplastic anemia (AA) is a rare disorder characterized by suppression of bone marrow function. It can develop as the result of congenital marrow disease and chemical exposure; however, most cases are idiopathic.1 Treatment with immunosuppressive therapy (IST) for patients who do not have an human leukocyte antigen (HLA)-compatible donor relies on the evidence that a deregulated immune system drives T lymphocytes to cytokine-mediated destruction of their own hematopoietic stem cells.1 The majority of these patients respond well to up-front administration of IST, including antithymocyte globulin (ATG) and cyclosporine (CsA), which is successful in around 80%.2 Unfortunately, ATG and CsA can lead to clonal disorders, in particular myelodysplastic syndrome (MDS) and paroxysmal nocturnal hemoglobinuria

Actions (login required)

Ver elemento